scholarly article | Q13442814 |
P50 | author | Pantelis A Sarafidis | Q89821637 |
P2093 | author name string | George L Bakris | |
Panagiotis I Georgianos | |||
P2860 | cites work | Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy | Q24657470 |
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes | Q28188162 | ||
Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? | Q28273680 | ||
Hyperkalemia and hyporeninemic hypoaldosteronism | Q28276420 | ||
Cardiorenal end points in a trial of aliskiren for type 2 diabetes | Q28278569 | ||
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators | Q28372091 | ||
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy | Q29615215 | ||
Trimethoprim-induced hyperkalemia: An analysis of reported cases | Q33679685 | ||
ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group | Q33922528 | ||
Drug-induced hyperkalemia: old culprits and new offenders | Q34038717 | ||
Regulation of potassium channel trafficking in the distal nephron | Q34117186 | ||
Beta-blockers, trimethoprim-sulfamethoxazole, and the risk of hyperkalemia requiring hospitalization in the elderly: a nested case-control study | Q34281438 | ||
Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. | Q34448201 | ||
Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors | Q34448983 | ||
Sodium zirconium cyclosilicate in hyperkalemia | Q34448992 | ||
Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial | Q34751971 | ||
Trimethoprim-sulfamethoxazole and risk of sudden death among patients taking spironolactone | Q35141436 | ||
Aldosterone in the development and progression of renal injury | Q35807297 | ||
Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system | Q35856246 | ||
Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. | Q36126918 | ||
Metabolic complications in elderly adults with chronic kidney disease. | Q36479806 | ||
The frequency of hyperkalemia and its significance in chronic kidney disease. | Q36530203 | ||
Antihypertensive therapy in the presence of proteinuria | Q36690664 | ||
Intestinal necrosis due to sodium polystyrene sulfonate (Kayexalate) in sorbitol | Q36802493 | ||
Timing of onset of CKD-related metabolic complications | Q37042178 | ||
Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review | Q37063760 | ||
Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors | Q37691122 | ||
Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers | Q37925006 | ||
Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms | Q37984206 | ||
Association of prescription of oral sodium polystyrene sulfonate with sorbitol in an inpatient setting with colonic necrosis: a retrospective cohort study. | Q38017494 | ||
Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice | Q38040078 | ||
Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy | Q38052452 | ||
Thiazide diuretics as chronic antihypertensive therapy in patients with severe renal disease--is there a role in the absence of diuresis? | Q38058500 | ||
Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review | Q38074251 | ||
Regulation of renal potassium secretion: molecular mechanisms | Q38129579 | ||
Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation? | Q38139240 | ||
Prediction and management of hyperkalemia across the spectrum of chronic kidney disease | Q38228688 | ||
Management of hyperkalaemia in chronic kidney disease | Q38249892 | ||
Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial | Q38408065 | ||
Heparin-induced aldosterone suppression and hyperkalemia | Q38572760 | ||
eGFR and creatinine clearance in relation to metabolic changes in an unselected patient population | Q43264358 | ||
Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy | Q43270031 | ||
Predictors of hyperkalemia risk following hypertension control with aldosterone blockade | Q43279459 | ||
Evaluation of the concurrent use of potassium-influencing drugs as risk factors for the development of hyperkalemia | Q43498899 | ||
Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease | Q43743641 | ||
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial | Q44218873 | ||
Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms | Q44272913 | ||
Combined angiotensin inhibition for the treatment of diabetic nephropathy | Q46129784 | ||
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 | ||
Telmisartan, ramipril, or both in patients at high risk of vascular events | Q46462657 | ||
Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study | Q46670272 | ||
Chlorthalidone for poorly controlled hypertension in chronic kidney disease: an interventional pilot study | Q48351927 | ||
Predictors of hyperkalemia and death in patients with cardiac and renal disease | Q48728677 | ||
P433 | issue | 14 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 2205-2215 | |
P577 | publication date | 2015-09-02 | |
P1433 | published in | Expert Opinion on Pharmacotherapy | Q5421212 |
P1476 | title | Advances in treatment of hyperkalemia in chronic kidney disease | |
P478 | volume | 16 |